KR970069035A - 새로운 진경제와 소염제의 합성 및 제조방법 - Google Patents
새로운 진경제와 소염제의 합성 및 제조방법 Download PDFInfo
- Publication number
- KR970069035A KR970069035A KR1019970013351A KR19970013351A KR970069035A KR 970069035 A KR970069035 A KR 970069035A KR 1019970013351 A KR1019970013351 A KR 1019970013351A KR 19970013351 A KR19970013351 A KR 19970013351A KR 970069035 A KR970069035 A KR 970069035A
- Authority
- KR
- South Korea
- Prior art keywords
- antispasmodic
- diclofegnac
- sodium
- inflammatory agent
- nonsteroidal anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002921 anti-spasmodic effect Effects 0.000 title claims abstract 15
- 229940124575 antispasmodic agent Drugs 0.000 title claims abstract 7
- 238000002360 preparation method Methods 0.000 title claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 239000000812 cholinergic antagonist Substances 0.000 claims abstract 16
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract 15
- 238000000034 method Methods 0.000 claims abstract 14
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 10
- 229910052708 sodium Inorganic materials 0.000 claims 10
- 239000011734 sodium Substances 0.000 claims 10
- -1 etodolak Chemical compound 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 3
- 150000003840 hydrochlorides Chemical class 0.000 claims 3
- 229960000965 nimesulide Drugs 0.000 claims 3
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- 239000011591 potassium Substances 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960003464 mefenamic acid Drugs 0.000 claims 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 2
- 229960003940 naproxen sodium Drugs 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 claims 1
- 239000000599 controlled substance Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010038419 Renal colic Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN792/DEL/96 | 1996-04-12 | ||
| IN792DE1996 IN187379B (enExample) | 1996-04-12 | 1996-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970069035A true KR970069035A (ko) | 1997-11-07 |
Family
ID=11091259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970013351A Ceased KR970069035A (ko) | 1996-04-12 | 1997-04-11 | 새로운 진경제와 소염제의 합성 및 제조방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5876751A (enExample) |
| JP (1) | JP3150642B2 (enExample) |
| KR (1) | KR970069035A (enExample) |
| CN (1) | CN1099285C (enExample) |
| AU (1) | AU695642B2 (enExample) |
| CA (1) | CA2202425A1 (enExample) |
| IN (2) | IN187379B (enExample) |
| NZ (1) | NZ314584A (enExample) |
| TW (1) | TW491702B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1218889E (pt) * | 1999-09-28 | 2010-03-08 | Panacea Biotec Ltd | Composições de libertação controlada compreendendo nimesulida |
| PL1667664T3 (pl) * | 2003-09-24 | 2017-06-30 | Novartis Consumer Health S.A. | Powlekane tabletki diklofenaku |
| CN106580886A (zh) * | 2016-12-05 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | 一种双氯芬酸钾散剂及其制备方法 |
| JP7025129B2 (ja) * | 2017-05-17 | 2022-02-24 | 小林製薬株式会社 | 筋痙攣治療剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA261585A (en) * | 1926-06-08 | P. Gail John | Mattress | |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2638970A1 (fr) * | 1988-11-16 | 1990-05-18 | Corbiere Jerome | Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention |
| KR920002149A (ko) * | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | 비스테로이드계 소염제에 의해 유발된 위장 장애 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법 |
| AU662160B2 (en) * | 1991-07-04 | 1995-08-24 | Taisho Pharmaceutical Co., Ltd. | Analgesic |
-
1996
- 1996-04-12 IN IN792DE1996 patent/IN187379B/en unknown
-
1997
- 1997-03-26 US US08/824,409 patent/US5876751A/en not_active Expired - Fee Related
- 1997-03-26 CN CN97104932A patent/CN1099285C/zh not_active Expired - Fee Related
- 1997-04-11 CA CA002202425A patent/CA2202425A1/en not_active Abandoned
- 1997-04-11 KR KR1019970013351A patent/KR970069035A/ko not_active Ceased
- 1997-04-11 AU AU17861/97A patent/AU695642B2/en not_active Ceased
- 1997-04-11 NZ NZ314584A patent/NZ314584A/en unknown
- 1997-04-14 JP JP09550097A patent/JP3150642B2/ja not_active Expired - Fee Related
- 1997-10-20 TW TW086115420A patent/TW491702B/zh not_active IP Right Cessation
-
2000
- 2000-03-22 IN IN289DE2000 patent/IN187310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1099285C (zh) | 2003-01-22 |
| TW491702B (en) | 2002-06-21 |
| IN187379B (enExample) | 2002-04-13 |
| JP3150642B2 (ja) | 2001-03-26 |
| JPH1036258A (ja) | 1998-02-10 |
| IN187310B (enExample) | 2002-03-23 |
| CN1218692A (zh) | 1999-06-09 |
| AU695642B2 (en) | 1998-08-20 |
| AU1786197A (en) | 1998-01-08 |
| NZ314584A (en) | 1998-05-27 |
| US5876751A (en) | 1999-03-02 |
| CA2202425A1 (en) | 1997-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2222323C2 (ru) | Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты | |
| ES2235152T3 (es) | Un compuesto que comprende un material tramadol y un antiinflamatorio no esteroide. | |
| US20240409514A1 (en) | Methods for inhibiting native and promiscuous uptake of monoamine neurotransmitters | |
| RU99119084A (ru) | Фармацевтические композиции для контролируемого высвобождения активных веществ | |
| KR870002832A (ko) | 제약 조성물 | |
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| ATE99927T1 (de) | Pharmazeutische formulierungen. | |
| KR920702216A (ko) | 아세틸 d-카르니틴의 녹내장 치료에의 용도 | |
| KR930009605A (ko) | 소염 또는 진통제 | |
| KR960031422A (ko) | 신규한 레티노이드 | |
| KR940021054A (ko) | 캡슐형 유비데카레논 경구 제제 | |
| EP1377285A1 (en) | Pharmaceutical composition comprising ibuprofen and prochlorperazine | |
| US20130224304A1 (en) | Effervescent nutritional and/or dietary supplement composition | |
| EP1017388A1 (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| JPH04288016A (ja) | 活性型ビタミンｄ３類軟カプセル剤の製造方法 | |
| CN109789152A (zh) | 双组分组合物 | |
| KR940003552A (ko) | 지방산을 이용한 석회화 예방 및 치료방법 | |
| EE9600202A (et) | Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm | |
| JP2011046666A (ja) | 医薬組成物 | |
| RU2006142706A (ru) | Новые составы оспемифена для перорального применения | |
| KR970700505A (ko) | 산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same) | |
| ATE210428T1 (de) | Geschmacksmaskierte wässrige lösungen enthaltend ibuprofen und menthol | |
| FR2587213A1 (fr) | Medicament pour le traitement de la dependance aux psychostimulants | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| RU97121485A (ru) | Лекарственное средство, активирующее процессы обмена веществ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19970411 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19970411 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19981214 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 19990629 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 19981214 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |